OTC Pink® Basic Disclosure Guidelines

Federal securities laws, such as Rules 10b-5 and 15c2-11 of the Securities Exchange Act of 1934 ("Exchange Act") as well as Rule 144 of the Securities Act of 1933 ("Securities Act"), and state Blue Sky laws, require issuers to provide *adequate current information* to the public markets. With a view to encouraging compliance with these laws, OTC Markets Group has created these OTC Pink Basic Disclosure Guidelines. We use the basic disclosure information provided by OTC Pink companies under these guidelines to designate the appropriate tier in the OTC Pink marketplace: Current, Limited or No Information. OTC Markets Group may require companies with securities designated as Caveat Emptor to make additional disclosures in order to qualify for OTC Pink Current Information tier.

Qualifications for the OTC Pink - Current Information Tier

Companies that make the information described below publicly available on a timely basis (90 days after fiscal year end for Annual Reports; 45 days after each fiscal quarter end for Quarterly Reports) qualify for the Current Information Tier. Financial reports must be prepared according to U.S. GAAP or IFRS, but are *not required to be audited* to qualify for the OTC Pink Current Information tier.

Initial Qualification:

1. Subscribe to the OTC Disclosure & News Service on www.OTCIQ.com to publish your financial reports and material news.
2. Create the following documents, save them in PDF format and upload them via www.OTCIQ.com:

- Annual Financial statements (Document must Include: Balance Sheet, Income Statement, Statement of Cash Flows, Notes to Financial Statements) for the previous two fiscal years. If these reports are audited, please attach the audit letter from the PCAOB registered audit firm. Each year's Annual Financial statements should be posted separately under the report type "Annual Report" in OTCIQ.
- Any subsequent Quarterly Reports since the most recent Annual Report.
- The most recent fiscal period end report should also include information in accordance with these OTC Pink Basic Disclosure Guidelines; use the fillable form beginning on page 3.

3. If financial reports are not audited by a PCAOB registered audit firm:

- Submit a signed Attorney Letter Agreement (first two pages of the Attorney Letter Guidelines).
- After following the appropriate procedures with a qualified attorney, upload an Attorney Letter complying with Attorney Letter Guidelines through your otciq.com account.

Ongoing Qualification:

1. **For each Fiscal Quarter End**, upload a Quarterly Report via www.OTCIQ.com within **45** days of the quarter end. (A separate quarterly report is not required for the 4th quarter.) The Quarterly Report should include:

- Information in accordance with these OTC Pink Basic Disclosure Guidelines -- use the fillable form beginning on page 3.
- Quarterly financial statements (Balance Sheet, Income Statement, Statement of Cash Flows, Notes to Financial Statements).
- No Audit Letter or Attorney Letter is required**.**

2. **For each Fiscal Year End**, upload an Annual Report within **90 days** of the fiscal year end. The Annual Report should include:

- Information in accordance with these OTC Pink Basic Disclosure Guidelines -- use the fillable form beginning on page 3.
- Annual financial statements (Balance Sheet, Income Statement, Statement of Cash Flows, Notes to Financial Statements, and Audit Letter, if the financial statements are audited).

3. If financial reports are not audited by a PCAOB registered audit firm, upload an Attorney Letter via www.OTCIQ.com complying with the Attorney Letter Guidelines within **120 days** of the fiscal year end.

Qualifications for the OTC Pink - Limited Information Tier

Companies that make the information described below publicly available within the prior 6 months qualify for the Limited Information Tier.

1. Subscribe to the OTC Disclosure & News Service on www.OTCIQ.com to publish your financial reports and material news.
2. Create a Quarterly Report or Annual Report for a fiscal period ended within the previous 6 months, save it in PDF format and upload it via www.OTCIQ.com. The Quarterly Report or Annual Report includes:

- Balance Sheet, Income Statement, and Total Number of Issued and Outstanding Shares. Financial statements must be prepared in accordance with US GAAP, but are not required to be audited. (Please note that Cash Flow Statements are not required to qualify for the Limited Information tier; however, unless the financial statements include a Cash Flow Statement, no financial data will be included in the OTC Financials Data Service, which distributes company financial data to online investor portals and makes the data available on your company's Financials tab on www.otcmarkets.com)
- A company in the Limited Information tier, may, but is not required to, include information in accordance with these OTC Pink Basic Disclosure Guidelines using the fillable form beginning on page 3.

Current Reporting of Material Corporate Events

OTC Markets Group encourages companies to make public disclosure available regarding corporate events that may be material to the issuer and its securities. Persons with knowledge of such events would be considered to be in possession of material nonpublic information and may not buy or sell the issuer's securities until or unless such information is made public. If not included in the issuer's previous public disclosure documents or if any of the following events occur after the publication of such disclosure documents, the issuer shall publicly disclose such events by disseminating a news release within 4 business days following their occurrence, and posting such news release through the OTC Disclosure & News Service.

Material corporate events include:

- Entry or Termination of a Material Definitive Agreement
- Completion of Acquisition or Disposition of Assets, Including but not Limited to mergers
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of an Issuer
- Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
- Costs Associated with Exit or Disposal Activities
- Material Impairments
- Sales of Equity Securities
- Material Modification to Rights of Security Holders
- Changes in Issuer's Certifying Accountant
- Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
- Changes in Control of Issuer
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
- Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Amendments to the Issuer's Code of Ethics, or Waiver of a Provision of the Code of Ethics
- Other events the issuer considers to be of importance

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)
In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.
Ascendant Solutions, Inc.

2) Address of the issuer's principal executive offices
Company Headquarters
Address 1: 16250 Knoll Trail Dr. Suite 102, Dallas TX 75248
Address 2:
Address 3:
Phone: 972-250-0945
Email: mheil@ascendantsolutions.com
Website(s): ascendantsolutions.com

IR Contact
Address 1: 14651 Dallas Parkway, Suite 800, Dallas TX 75254
Address 2:
Address 3:
Phone: 972-458-8000
Email: gdebusk@halliburtonir.com
Website(s): halliburtonir.com

3) Security Information
Trading Symbol: ASDS
Exact title and class of securities outstanding: Common Stock
CUSIP: 04349Y107
Par or Stated Value: $0.0001
Total shares authorized: 50,000,000 as of: 3/31/16
Total shares outstanding: 22,096,756 as of: 3/31/16
Additional class of securities (if necessary): N/A

Transfer Agent
Name: Securities Transfer Corporation
Address 1: 2591 Dallas Parkway Suite 102, Frisco TX 75034
Address 2:
Address 3:
Phone: 469-633-0101
Is the Transfer Agent registered under the Exchange Act?* Yes: ☒ No: ☐
*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.
List any restrictions on the transfer of security: None
Describe any trading suspension orders issued by the SEC in the past 12 months: None
List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

- On June 27, 2015, Ascendant Solutions, Inc. through its Healthcare subsidiary, Dougherty's Holdings, acquired Medicine Shoppe pharmacy ("McAlester"), located in McAlester, Oklahoma.
- On August 31, 2015, Ascendant Solutions, Inc. through its Healthcare subsidiary, Dougherty's Holdings, acquired Springtown Drug pharmacy ("Springtown"), located in Springtown, Texas.
- On December 14, 2015 the Company issued a special 1 percent common stock dividend.

4) Issuance History
List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:
A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.); None

B. Any jurisdictions where the offering was registered or qualified; None
C. The number of shares offered; None

D. The number of shares sold; None
E. The price at which the shares were offered, and the amount actually paid to the issuer; None
F. The trading status of the shares; None and
G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

- 30,000 Restricted Stock Units issued November 13, 2014 to directors
- $.0001 per share dividend to stockholders of record on December 1, 2014 resulting in 216,086 new shares
- 10,100 Restricted Stock Units issued April 15, 2015 to an officer
- 20,200 Restricted Stock Units issued June 3, 2015 to directors
- 30,300 Restricted Stock Units issued November 13, 2015 to directors
- $.0001 per share dividend to stockholders of record on December 7, 2015 resulting in 218,560 new shares

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

A. Balance sheet;
B. Statement of income;
C. Statement of cash flows;
D. Financial notes; and
E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

The Company's financial statements for the period ended March 31, 2016, including (A) Consolidated Balance Sheets as of March 31, 2016 and December 31, 2015, (B) Statements of Operations for the three months ended March 31, 2016 and March 31, 2015, (C) Statements of Cash Flows for the years ended March 31, 2016 and March 31, 2015 can be reviewed in the "Quarterly Report-March 31, 2016 Financial Statements" that were posted to otciq.com on May 13, 2016.

(D) Notes to Financial Statements

1. Basis of Presentation

The interim consolidated financial statements of Ascendant Solutions, Inc. ("Ascendant" or the "Company") for the period ended March 31, 2016 have not been audited by our independent registered public accounting firm. The December 31, 2015 balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The interim consolidated financial statements and notes thereto should be read in conjunction with the financial statements and notes included in the audited consolidated financial statements for the year ended December 31, 2015. In the opinion of management, these interim financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim periods presented.

Certain amounts in the prior year's consolidated financial statements have been reclassified to conform to the current year presentation.

2. Investment

The estimated value of the investment in CRESA Partners of Orange County, L.P, "CPOC", of $5,107,000 as of March 31, 2016 and December 31, 2015, is accounted for under the cost method of accounting. CPOC is located in Newport Beach, California and provides performance based corporate real estate advisory services to corporate clients around the United States, such as tenant representation services to commercial and industrial users of real estate.

3. Deferred Tax Asset

Significant components of the net deferred tax assets at December 31 are as follows:

Current deferred income tax assets:	
Allowance for doubtful accounts	$ 11,000
Inventory reserves	12,000
Income from Pass-through	63,000
UNICAP – Sec 263A	41,000
Accrued liabilities	20,000
Net current deferred income tax assets	147,000
Valuation allowance	(147,000)
	$ -
Non-current deferred income tax assets:	
Net operating loss carryforward	$ 14,777,000
Alternative minimum tax credit	220,000
Other	142,000
	15,139,000
Non-current deferred income tax liabilities:	
Property and equipment	-
Net non-current deferred income tax assets	15,139,000
Valuation allowance	(12,139,000)
Net non-current deferred income tax asset	$ 3,000,000

As of December 31, 2015, the Company had approximately $220,000 of alternative minimum tax credits available to offset future federal income taxes. The credits have no expiration date. The Company also has unused operating loss carryforwards of $43,463,000 which expire between 2020 and 2032.

4. Commitments and Contingencies

Guarantee

The Company remains a co-guarantor on a related party's promissory note with a bank that is secured with collateral.

Legal Proceedings

The Company is occasionally involved in other claims and proceedings, which are incidental to its business. It is the opinion of management that the disposition or ultimate resolution of such claims and lawsuits will not have a material adverse effect on the consolidated financial position, results of operations and cash flows of the Company.

5. Notes Payable

Notes payable consist of the following:

	Mar 31, 2016	Dec 31, 2015
First National Bank Southwest Credit Facility, secured by certain retail pharmacy assets		
Revolving line of credit in the principal amount of $4,750,000, interest at LIBOR plus 3.25% (3.69% at March 31, 2016) payable monthly, matures May 2016.	$ 3,500,000	$ 4,126,000
Cardinal Health Term Note, secured by certain retail pharmacy assets		
Term note in the principal amount of $1,500,000 with interest payable at 6.0% per annum payable in monthly installments of $17,861 plus interest, a final payment of $446,533 plus all accrued and unpaid interest due in full on February 17, 2017.	607,000	661,000
Term note in the principal amount of $1,827,850 with interest payable at 5.85% per annum payable in monthly installments of $15,232 plus interest, a final payment of $929,157 plus all accrued and unpaid interest due in full on July 10, 2020.	1,691,000	1,736,000
Term note in the principal amount of $1,241,350 with interest payable at 5.85% per annum payable in monthly installments of $10,344 plus interest, a final payment of $638,850 plus all accrued and unpaid interest due in full on January 10, 2020.	1,086,000	1,117,000
Term note in the principal amount of $744,100 with interest payable at 5.63% per annum payable in monthly installments of $6,200 plus interest, a final payment of $378,251 plus all accrued and unpaid interest due in full on August 10, 2020.	700,000	719,000
Term note in the principal amount of $305,350 with interest payable at 5.65% per annum payable in monthly installments of $2,545 plus interest, a final payment of $155,220 plus all accrued and unpaid interest due in full on August 10, 2019.	254,000	262,000
Term note in the principal amount of $168,350 with interest payable at 5.85% per annum payable in monthly installments of $2,004 plus interest, a final payment of $50,356 plus all accrued and unpaid interest due in full on September 10, 2019.	130,000	136,000
Prebate of monthly source rebate	530,000	-
Acquisition Notes Payable , unsecured		
Notes payable to sellers of acquired pharmacies with varying monthly payments with interest at 5.5% due through September 2018.	496,000	514,000
Insurance notes payable, secured by the respective insurance policies		
Notes payable for the Company's insurance policy premiums with varying monthly payments due through September 2016. Interest rates vary up to 3.16%	112,000	173,000
Equipment notes payable, secured by the respective equipment		
Notes payable for equipment purchased with varying monthly payments due through August 2016. Interest vary up to 9.88%	10,000	62,000
	9,116,000	9,506,000
Less current portion	(1,010,000)	(1,088,000)
	$ 8,106,000	$ 8,418,000

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations:

- Ascendant Solutions, Inc. ("Ascendant") is a value oriented investment firm focused on successfully acquiring, managing and growing community based pharmacies in the Southwest Region.

Date and State (or Jurisdiction) of Incorporation: August 22, 2000 Delaware

B. the issuer's primary and secondary SIC Codes; 6799 (Investors) 5912 (Drug Stores)
C. the issuer's fiscal year end date; Calendar Year
D. principal products or services, and their markets:

Ascendant Solutions, Inc. is a value-oriented investment firm focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region. Ascendant currently has approximately $42 million in net operating loss carryforwards which can be used to shelter future income, thus enhancing free cash flow or debt service capabilities. Interested investors can access financials and stock trading information for Ascendant at OTCMarkets.com or at www.ascendantsolutions.com.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.
In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership. If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

- Dougherty's Retail Pharmacy located at 5959 Royal Lane, Dallas Texas 75230. Approx.13,000 sq ft leased
- Dougherty's Retail Pharmacy located at 11970 N. Central Expy, Dallas Texas 75243. Approx. 6,000 sq ft leased
- Dougherty's Retail Pharmacy located at 211 FM1960 Bypass Rd East, Humble, TX 77338. Approx. 3,000 sq ft leased
- Dougherty's Retail Pharmacy located at 6151 Dew Dr. Ste. 100, El Paso, TX. 79912. Approx. 3,000 sq ft leased
- Dougherty's Retail Pharmacy located at 622 E Wyandotte Ave, McAlester, OK 74501. Approx. 3,000 sq ft leased
- Dougherty's Retail Pharmacy located at 117 E. First St., Springtown, TX 76082. Approx. 3,000 sq ft leased
- Corporate and Real Estate Advisory Services offices located at 16250 Knoll Trail Drive, Suite 102, Dallas Texas 75248. Approx. 3,000 sq ft leased

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

- James C. Leslie, Chairman of the Board
- Mark Heil, President and Chief Financial Officer
- Will Cureton, Director
- Anthony LeVecchio, Director
- Curt Nonomaque, Director

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); none
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; none
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; none or
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities. none

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders. none

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Firm: Winstead PC
Address 1: 2728 N. Harwood Street Dallas, Texas 75201 Phone: 214-745-5400

Accountant or Auditor
Firm: Whitley Penn
Address 1: 8343 Douglas Avenue Suite 400 Dallas, TX 75225 Phone: (972) 393-9300

Investor Relations Consultant
Firm: Halliburton Investor Relations & Communications
Address 1: 14651 Dallas Pkwy #800 Dallas, TX 75254 Phone: (972) 458-8000

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement. Name: None

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).
The certifications shall follow the format below:

I, Mark S. Heil certify that:

1. I have reviewed this Annual Disclosure Statement of Ascendant Solutions, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 13, 2016
/s/ Mark Heil
President and Chief Financial Officer